Chengzhong Cai
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Tongji University (2015–2016); United States Food and Drug Administration (2016–2024); Philipps University of Marburg (2022); Heidelberg University (2020); Universitätsklinikum Gießen und Marburg (2010–2022); University Hospital Heidelberg (2020); First Affiliated Hospital of Guangzhou Medical University (2024); Shanghai Tenth People's Hospital (2015–2016); University Medical Centre Mannheim (2020); Guangzhou Medical University (2024)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Chengzhong Cai's research program investigates molecular mechanisms underlying disease and explores novel diagnostic and therapeutic strategies. His work has focused on identifying key proteins involved in cell proliferation, such as the importin beta superfamily member RanBP17, and its association with patient survival in HPV+ head and neck squamous cell carcinoma. Cai has also contributed to the development of predictive models for drug-induced cardiotoxicity, utilizing induced pluripotent stem cell-derived cardiomyocytes. Furthermore, his research extends to the application of mass spectrometry for early cancer screening, including a model for accurate prostate cancer detection through urine protein enrichment. His scholarship metrics include an h-index of 11, with 26 total publications and 404 citations. Cai has collaborated with several researchers at the National Center for Toxicological Research, including Vikrant Vijay, William B. Mattes, Katy S Papineau, and Lijun Ren.
Metrics
- h-index: 11
- Publications: 26
- Citations: 409
Selected Publications
-
Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin (2024)
-
Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools (2020)
-
Sex differences in repolarization reserve, a possible mechanism for sex-related differences in drug-induced QT prolongation and torsades de pointes (2019)
-
MS07.2 Sex Difference of Repolarization Reserve On Drug-induced QT Prolongation and Arrhythmias (2018)
-
Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs (2018)
-
Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in vivo flow cytometry (2017)
-
<i>In vivo</i> noninvasive analysis of graphene nanomaterial pharmacokinetics using photoacoustic flow cytometry (2017)
-
Photoacoustic flow cytometry for nanomaterial research (2017)
-
Photoacoustic Flow Cytometry for Single Sickle Cell Detection<i>In Vitro</i>and<i>In Vivo</i> (2016)
-
In vivo photoacoustic flow cytometry for early malaria diagnosis (2016)
-
In Vivo Long-Term Monitoring of Circulating Tumor Cells Fluctuation during Medical Interventions (2015)
-
Anatomical study of surgical approaches for minimally invasive transoral thyroidectomy: eMIT and TOPP (2015)
Collaboration Network
Top Collaborators
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
Similar Researchers
Based on overlapping research topics